Rising bedaquiline resistance: exploring potential causes and next steps

Authors:

Abstract
Although the estimated incidence of multidrug-resistant (MDR)/rifampicin-resistant (RR) tuberculosis (TB) has been relatively stable in recent years, MDR/RR-TB still represents a significant public health threat, with an estimated number of 400 000 new cases in 2023 [1]. The US Food and Drug Administration granted bedaquiline (BDQ) accelerated approval in 2012, and although the label does not include recommendations for the treatment of RR-TB, BDQ is being incorporated into all guideline-recommended standard regimens for MDR/RR-TB worldwide [1, 2].
Funding Information
  • Innovative Medicines Initiative (101007873)

This publication has 26 references indexed in Scilit: